Value of CgA and NSE as predictors of tumor response after combined PRRT and CAPTEM therapy in patients with progressive, advanced GEP-NET

#3284

Introduction: Combine PRRT and CAPTEM is a new approach in therapy of NET.

Aim(s): To assess CgA & NSE as predictors of tumor response based on objective response rate (ORR) & clinical response after combined therapy PRRT and CAPTEM in progressive, advanced, unresectable GEP-NET.

Materials and methods: Prospective, single arm, open-label study, in patients with histologically proven GEP-NET, NCT04194125. Overall 21 patients, (panNET) n=14 and midgut n=7 All underwent combination therapy using 177Lu DOTATOC & CAPTEM, followed for at least 18 months. Disease status and treatment efficiency were evaluated by clinical assessment and ORR RECIST. CgA and NSE were evaluated before, during and after therapy as follow-up, calculated as median upper limit normal ULN value.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ćwikła J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Nowicka G, Włodarczyk M, Nowicki M,

Keywords: CgA, NSE, neuroendocrine tumor, PRRT and CAPTEM,